Highest-materiality recent filing
Dermata raises $3.4M in private placement of shares and warrants
Gross proceeds ~$3.4M; net ~$3.2M after expenses; closing expected Aug 18, 2026.
Dermata to launch Tome Foundational Treatment on Aug 25, 2026; cash $4.4M
Tome Foundational Treatment launch expected Aug 25, 2026; manufacturing and packaging complete.
Dermata announces Aug 25 launch of Tome Foundational Treatment at $178 per set
First commercial product Tome Foundational Treatment launches August 25, 2026; waitlist gets early preorder access.
Dermata Therapeutics pivots to DTC skincare; reports year-end 2025 cash of $7.5M
Strategic pivot from prescription derm to direct-to-consumer skincare brand Tome; first product launch mid-2026.
Dermata raises $4.1M (up to $12.4M) in private placement at $2.04/share for OTC acne kit launch
Gross proceeds of ~$4.1M upfront; potential additional ~$8.3M from full warrant exercise for total up to $12.4M.
Dermata terminates Villani license, pivots to OTC skin care
Terminated license agreement with Villani Inc.; effective 90 days after Nov 17, 2025 notice.
Dermata Therapeutics pivots to OTC; plans acne kit launch mid-2026, reports Q3 cash $4.7M
Cash and cash equivalents of $4.7M as of Sep 30, 2025; expected to fund operations into Q2 2026.
Dermata reports statistically significant Phase 3 XYNGARI acne data vs placebo at EADV 2025
IGA 2-point reduction + clear/almost clear at Week 12: 29.4% XYNGARI vs 15.2% placebo (p<0.001).
Dermata pivots to OTC dermatology, withdraws XYNGARI IND, plans acne kit launch mid-2026
Strategic shift to prioritize OTC dermatology products sold directly to consumers.
Dermata Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq non-compliance notice on May 14, 2025 due to bid price below $1.00.
Dermata reports positive Phase 3 STAR-1 data, Q2 2025 cash $6.5M
XYNGARI™ Phase 3 STAR-1 met all three co-primary endpoints with statistical significance at weeks 4 and 12.
Dermata Therapeutics to effect 1-for-10 reverse stock split effective August 1, 2025
Reverse stock split at 1:10 ratio effective 12:01 a.m. ET on August 1, 2025.
Nasdaq Panel grants Dermata Therapeutics exception until Aug 14, 2025 to meet minimum bid price rule
Company received Nasdaq delisting notice on May 14, 2025 for failing minimum $1.00 bid price over 30 consecutive days.
Dermata Therapeutics faces Nasdaq delisting for minimum bid price; plans hearing
Regained compliance with Nasdaq stockholders' equity requirement on May 14, 2025.
Dermata: XYNGARI Phase 3 STAR-1 acne trial meets co-primary endpoints; cash $9.7M
XYNGARI Phase 3 STAR-1 achieved statistically significant results on all co-primary endpoints at all time points vs placebo.
Dermata's XYNGARI Phase 3 trial shows stat sig benefit at 4 weeks in moderate-to-severe acne
IGA treatment success: 11.9% XYNGARI vs 6.2% placebo (p<0.05) at week 4, after 4 weekly doses.
Dermata raises ~$6.2M via warrant exercise at reduced price; issues new warrants
4,834,470 existing warrants exercised at reduced price of $1.284/share, yielding $6.2M gross proceeds.
Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance
STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).
Dermata Therapeutics receives Nasdaq delisting notice for failing minimum stockholders' equity
Nasdaq notified Dermata on March 25, 2025, of non-compliance with $2.5M minimum stockholders' equity rule.
Dermata reports FY2024 cash burn; Phase 3 STAR-1 topline expected by end of March 2025
Cash and cash equivalents $3.2M as of Dec. 31, 2024, down from $7.4M; expects funding into Q3 2025 after $2.55M Jan. 2025 PIPE.
Dermata raises $2.55M private placement at $1.27/unit with insider participation
Gross proceeds $2.55M; net ~$2.4M from 2,007,880 shares (or pre-funded warrants) and same number of warrants.
Dermata and Revance enter clinical trial collaboration for Xyngari with Daxxify in hyperhidrosis
Dermata and Revance will collaborate on a Phase 2a trial of topical Xyngari with Daxxify for moderate-to-severe axillary hyperhidrosis.
Dermata nears completion of DMT310 Phase 3 enrollment; Q3 2024 cash at $6.1M
Enrollment in DMT310 Phase 3 STAR-1 acne trial expected to complete by end of 2024; topline results Q1 2025.
Dermata raises $3.5M gross in private placement; expects cash runway into Q2 2025
Gross proceeds $3.5M from 1,912,569 shares/pre-funded warrants + Series A & B warrants at $1.83/unit.
Dermata Therapeutics enters ATM equity facility for up to ~$1.16M
ATM Agreement with H.C. Wainwright for at-the-market issuance of common stock up to $1,157,761 aggregate market value.
Dermata Therapeutics regains Nasdaq compliance with publicly held shares rule
Received Nasdaq deficiency notice on May 20, 2024 for failing Rule 5550(a)(4) requiring at least 500,000 publicly held shares.
Dermata raises $2.66M via immediate exercise of warrants at reduced price; issues new warrants
Exercise of 516,336 warrants at reduced exercise price of $5.16 per share for cash gross proceeds of ~$2.66M.
Dermata gets 180-day Nasdaq extension; files 1:15 reverse stock split to regain compliance
Received Nasdaq extension until November 11, 2024 to meet $1.00 minimum bid price.
Dermata Therapeutics Q1 2024 net loss $3.1M; cash runway into Q3 2024
Cash and equivalents $4.7M as of March 31, 2024, down from $7.4M at Dec 31, 2023.
Dermata shareholders approve reverse stock split (1:5-1:30) and equity plan expansion
Stockholders approved reverse stock split at ratio from 1:5 to 1:30, exact ratio to be set by Board.
Dermata Therapeutics receives Nasdaq delisting notice for bid price non-compliance
Nasdaq notice dated Nov 15, 2023 for failing $1.00 minimum bid price for 30 consecutive business days.
Dermata Therapeutics appoints Moss Adams as auditor, reports $6.6M cash, advances DMT310 to Phase 3
Appointed Moss Adams LLP as new auditor for FY2023, effective Nov 9, 2023, replacing MHM.
Dermata reports Q2 2023 cash $8.4M; FDA agrees Phase 3 design for DMT310 acne
Cash $8.4M at June 30, 2023 vs $6.2M at Dec 31, 2022; net $5.7M from two 2023 financings.
Dermata auditor MHM resigns; prior audits flagged going concern; equity plan expanded
MHM will not stand for reappointment as auditor for FY2024; will serve until FY2023 audit or new auditor appointed.
Christopher J. Nardo, Ph.D., the Company’s Senior Vice President of Development, was promoted to Senior Vice President, Chief Development Officer, effective July 1, 2022.
the Board increased its size from seven to eight directors and appointed Brittany Bradrick as a Class II director to fill the newly created vacancy.
appointed Kyri Van Hoose as Senior Vice President, Chief Financial Officer, effective immediately.
On September 1, 2021, Thomas Insley resigned as Chief Financial Officer of the Company.
Max materiality 0.90 · Median 0.65 · Most common event other_material